New Publication: Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
Home
>
Science Hub
>
New Publication:
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
April 11, 2024
Hartmut Koeppen et al. The Journal of Pathology
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
You might also be interested by
News
CellCarta and Sonic Healthcare Establish Strategic Partnership to Commercialize Companion Diagnostics Through Lab Network
May 27, 2026
More infoWeb News
New Automated CyTOF™ Cleanup Tool in CellEngine - Fast, Consistent, and Easy
May 26, 2026
More infoWeb News
The CellCarta–Leica Biosystems Partnership: A Coordinated Approach to CDx Development in China
May 8, 2026
More infoPosters
High quality whole transcriptome RNA-sequencing from challenging clinical samples
April 21, 2026
More info